Systemic treatment for metastatic colorectal cancer in the era of precision medicine
- PMID: 30802315
- DOI: 10.1002/jso.25421
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Abstract
The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.
Keywords: biomarkers; chemotherapy; colorectal cancer; immunotherapy; targeted therapy.
© 2019 Wiley Periodicals, Inc.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
